The Future of Idiopathic Pulmonary Fibrosis Treatment

The Future of Idiopathic Pulmonary Fibrosis Treatment

https://vimeo.com/157197415 In this video from CME Corner shared in 2016, Dr. Steven Nathan is joined by two prominent pulmonologists, Dr. Marilyn Glassberg and Dr. David Lederer, to participate in a roundtable discussion about the progress against idiopathic pulmonary fibrosis (IPF). Find out about eight ongoing research projects for…

The Exhaustion from IPF is More Than Physical

When you think of someone who has a lung disease, such as idiopathic pulmonary fibrosis (IPF), it is easy to understand that physical exhaustion is likely a primary side effect. What may not be so easy to understand, however, is the mental exhaustion that comes with having…

Explaining the Symptoms of Idiopathic Pulmonary Fibrosis

This animated video from Boehringer Ingelheim discusses the symptoms of idiopathic pulmonary fibrosis (IPF). The video explains that IPF is a rare lung condition which is notoriously difficult to diagnose and is often misdiagnosed as other more common lung diseases like COPD and asthma. Understand more about the facts of idiopathic…

Personalized Care for Idiopathic Pulmonary Fibrosis

In this PeerView Press video, pulmonologist Dr. David J. Lederer discusses idiopathic pulmonary fibrosis (IPF), with a focus on personalized care through communications and innovative strategies. He is joined by primary care physician Dr. Steven J. Antonini and pulmonary fibrosis patient Robert Brynteson. Read about six lesser-known symptoms of…

7 Health Benefits of Vitamin D

Vitamin D is often called the “sunshine vitamin,” mostly because we get it naturally when the sun’s UV rays interact with our skin, which triggers the vitamin’s synthesis. The vitamin helps our body’s absorption of calcium to keep our bones strong and encourage healthy cells to grow. Last year, researchers demonstrated the protective effects of vitamin…

Bleomycin-triggered Lung Disease May Be Treated with Esbriet, Case Report Suggests

A case report illustrates the possibility of treating cancer patients who develop bleomycin-triggered lung disease with Esbriet (pirfenidone) — a drug approved for idiopathic pulmonary fibrosis (IPF) treatment. Researchers acknowledged that further studies are needed, but they said combining Esbriet and corticosteroid drugs could completely reverse lung disease and prevent…